Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 13,289 Shares of Stock

Key Points

• Claire Mazumdar, CEO of Bicara Therapeutics, sold 13,289 shares at an average price of $18.84, totaling approximately $250,365, reducing her ownership by 4.11%.
• The stock is currently trading at $18.81 with a market cap of $1.03 billion and has a 50-day moving average of $12.77.
• Analysts have a consensus rating of "Moderate Buy" on BCAX shares, with an average target price of $31.86.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 13,289 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $18.84, for a total value of $250,364.76. Following the transaction, the chief executive officer directly owned 309,892 shares of the company's stock, valued at approximately $5,838,365.28. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Claire Mazumdar also recently made the following trade(s):

• On Monday, October 13th, Claire Mazumdar sold 11,445 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.92, for a total transaction of $216,539.40.

Bicara Therapeutics Price Performance

BCAX stock traded up $1.50 during trading on Wednesday, hitting $18.81. 700,861 shares of the stock traded hands, compared to its average volume of 581,907. The firm's 50 day moving average is $12.77 and its two-hundred day moving average is $11.92. The stock has a market cap of $1.03 billion and a price-to-earnings ratio of -5.93. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. As a group, analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently bought and sold shares of BCAX. Vestal Point Capital LP lifted its position in shares of Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company's stock worth $46,450,000 after buying an additional 2,231,025 shares during the last quarter. Braidwell LP lifted its position in shares of Bicara Therapeutics by 8.1% in the first quarter. Braidwell LP now owns 2,162,803 shares of the company's stock worth $28,181,000 after buying an additional 162,144 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Bicara Therapeutics by 84.0% in the first quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company's stock worth $18,173,000 after buying an additional 636,708 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock worth $6,248,000 after purchasing an additional 180,833 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Bicara Therapeutics by 2,351.0% during the 2nd quarter. Bank of America Corp DE now owns 451,228 shares of the company's stock worth $4,192,000 after purchasing an additional 432,818 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts recently weighed in on BCAX shares. Wedbush reiterated an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, August 12th. HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Tuesday. Finally, Piper Sandler started coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.